On February 2nd, the 'Accelerator-Based Medical Isotope Drug Research and Development Platform' (dubbed the IP-SAFE project), which was constructed by the Institute of Modern Physics under the Chinese Academy of Sciences, reached a new milestone. The main body of the accelerator device has been successfully installed on-site. This achievement represents a pivotal advancement in the development of the world's inaugural alpha medical isotope mass production demonstration facility, which is based on a superconducting linear accelerator.

Drawing upon the cutting-edge technology developed by the Institute of Modern Physics, the project is poised to realize large-scale production of crucial medical alpha isotopes, including actinium-225 and radium-223. This breakthrough is set to significantly reduce China's dependence on imported high-end medical nuclides, marking a transformative shift in the nation's medical isotope landscape.